Edited Transcript of CARA earnings conference call or presentation 7-May-19 8:30pm GMT

Thomson Reuters StreetEvents - finance.yahoo.com Posted 6 years ago
. So we hopefully will have that data in future calls to talk about, Frank." data-reactid="237">So that's the mechanism that I think the patients can benefit from. It should be pan-antipruritic, if you like. And of course, that's something hopefully we're going to produce more data on in terms of mechanism and the anti-inflammatory effect as we run through these larger trials where we are looking at biologic markers as part of our exploratory measurement. So we hopefully will have that data in future calls to talk about, Frank.

--------------------------------------------------------------------------------

François Daniel Brisebois, Laidlaw & Company (UK) Ltd., Research Division - Healthcare Equity Analyst [37]

--------------------------------------------------------------------------------

All right. And I just -- so there's no -- is there for you guys kind of a reason why maybe things wouldn't translate as well from PBC to NASH just because it seems like -- and obviously, drugs aren't approved yet for NASH. But it seems like the pruritic effect is larger than may be expected. So is there any reason when you speak to hepatologists that this might be easier in PBC? Or we'll just have to see for that?

--------------------------------------------------------------------------------

Derek T. Chalmers, Cara Therapeutics, Inc. - Co-Founder, President, CEO & Director [38]

--------------------------------------------------------------------------------

Yes. No. So -- look there's certainly a great need, that's the message we get in speaking to hepatologists and KOLs that there's a great need for effective antipruritics for that patient population. It looks as though we have more consistency in PBC. So for us, that makes sense as the first group we look at. It doesn't mean that ultimately we won't look at other groups within that heterogeneous population, but that consistency of response is important for our first clinical trial, and that's where we're going to focus initially.

--------------------------------------------------------------------------------

Operator [39]

--------------------------------------------------------------------------------

And I'm showing no further questions. And I would like to turn the conference back over to CEO, Derek Chalmers, for closing remarks.

--------------------------------------------------------------------------------

Derek T. Chalmers, Cara Therapeutics, Inc. - Co-Founder, President, CEO & Director [40]

--------------------------------------------------------------------------------

So thank you, everybody. Thanks for participating in today's call. I'd like to thank particularly the Cara team for all their hard work and commitment. I'd like to thank our investors, our study investigators and, most importantly, the patients who participate in our ongoing large clinical trials. And we look forward to talking to everybody again very soon. So thank you very much, everybody.

--------------------------------------------------------------------------------

Operator [41]

--------------------------------------------------------------------------------

Ladies and gentlemen, this concludes today's call. Thank you again for your participation. You may now disconnect. Have a great day.